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ABSTRACT
The increased use of antibodies and antibody fragments for human 
therapy is driving the search for rational approaches to accelerate bioprocess 
development. However, screening of the operating conditions of process 
parameters in large scale bioreactors for biopharmaceuticals industry is not 
cost effective. Using microwell plate as the ‘microreactof for screening 
process would be a solution to this, Hence, this study was carried out to 
evaluate multi-well based system by determining the growth rate and 
antibody expression of the Chinese hamster ovary (CHO) cells. In this study, 
two types of CHO cells have been seeded with different concentrations which 
were 7*1 O'1 cell/ml and 1*106 cell/ml. Wild type CHO cell and CHO DG44 
were used in this study. The wild type CHO cell was used as a reference cell 
as it is a stable cell. The cell number wras calculated by using trypan blue 
exclusion method while glucose concentration was determined by 3. 5- 
Dinitrosalicyclic acid (DNS) assay. On the other hand, antibody production 
was determined by using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blot. For the cell growth rate and 
doubling time. CHO DG44 (lxlO6 cell/ml) has recorded the highest growth 
rate and shortest doubling time with (0.3301 ± 0.1536)/h and (2.61 ±1.66)h. 
Besides that the highest glucose concentration recorded by wild type CHO 
cell ( lx l 06 cell/ml) and CHO DG44 (7X103 cell/ml) was on day 0 of 
incubation with (1.817+0.1187)mg/ml and (1.819±0.9331)mg/ml. 
Meanwhile. CHO DG44 (1><106 cell/ml) has recorded the highest glucose 
concentration on day 1 with (1.61 l±0.1273)mg/ml. Lastly, the antibody 
expression by CHO DG44 wras verified. Both batches of CHO DG44 have 
successfully expressed human IgG on day 2 until day 10. In conclusion, the 
CHO cell is possible to be cultured in the multi-well plate.
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ABSTRAK
Peningkatan penggunaan antibodi untuk terapi manusia mendorong 
pencarian untuk pendekatan rasional untuk mempercepatkan pembangunan 
bioproses. Walaubagaimanapun. penyaringan awal bagi kondisi parameter 
proses untuk bioreaktor berskala besar bagi industri biofarmaseutikal 
memakan belanja yang besar. Penggunaan plat multi-well sebagai 
‘mikroreaktor’ mungkin dapat menyelesaikan masalah ini. Oleh itu. kajian ini 
dijalankan untuk mcnilai sisteni berasaskan multi-well melalui penentuan 
kadar pertumbuhan dan antibody ekspresi yang dihasilkan oleh sel ovari 
hamster China (CHO). Di dalam kajian ini. dua jenis sel CHO telah dikultur 
dengan kepekatan yang berbeza iaitu 7  ^10" sel/ml dan lxlO6 sel/ml. Sel 
CHO jenis bukan mutan dan CHO DG44 telah digunakan di dalam kajian ini 
dimana sel CHO jenis bukan mutan digunakan sebagai rujukan kerana ia 
merupakan sel yang stabil. Bilangan sel telah dikira menggunakan kaedah 
penyisihan trypan biru manakala kepekatan glukosa ditentukan dengan ujian 
3. 5-Dinitrosalicyclic (DNS). Seterusnya, penghasilan antibodi ditentukan 
dengan menggunakan elektroforesis gel polyacrylamide natrium dodecyl 
sulfate (SDS-PAGE) dan blot Barat. Bagi kadar pertumbuhan dan masa 
penggandaan sel, CHO DG44 (1*106 sel/ml) telah merekodkan kadar 
pertumbuhan tertinggi dan masa penggandaan tersingkat dengan (0.3301 ±
0.1536)/jam dan (2.61 ±1.66)jam. Selain itu, kepekatan glukosa yang 
tertinggi yang telah direkodkan oleh CHO sel bukan jenis mutan (lxlO6 
sel/ml) dan CHO DG44 (7x10'"' sel/ml) adalah pada hari 0 dengan nilai 
(1.817±0.1187)mg/ml dan (1.819±0.9331)mg/ml. Sementara itu, CHO DG44 
(lxlO6 sel/ml) telah merekodkan kepekatan glukosa tertinggi pada hari 
pertama inkubasi dengan nilai (1.61 l±0.1273)mg/ml. Akhir sekali, antibodi 
eskpresi oleh CHO DG44 telah disahkan. Kedua-dua CHO DG44 telah 
berjaya mengekspresi antibodi bermula pada hari kedua hingga hari 
kesepuluh. Secara keseluruhan, CHO sel berkemungkinan untuk dikultur di 
plat multi-well.
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CHAPTER 1
INTRODUCTION
1.1 Background of Study
Emerging technologies on therapeutic protein production has set a new level 
of development in medical research. The production of therapeutic protein focuses 
on finding the cure for diseases such as cancer and autoimmune disease. In 
biopharmaceutical industry, various new monoclonal antibodies (MAbs) and 
recombinant proteins are estimated to enter preclinical and clinical development 
every year (Durocher & Butler, 2009).
Birch and Okunle (2005) stated that various sources such as bacteria and 
fungi have been used in traditional production of recombinant protein. Escherichia 
coli is one of the sources used to produce human insulin and growth hormone 
(Agrawal & Bal, 2012). The usage of bacteria as the producer of recombinant 
antibody production is said to be the most economics in expenditure. This is due to 
its robust characteristic, short term production cycle, low cost in strain establishment 
and higher productivity compared to the mammalian cell. However, bacteria do not 
able to perform posttranslational protein modification unlike mammalian cell line 
such as Chinese hamster ovary (CHO) cell and baby hamster kidney (BHK) cell 
(Dingermann, 2008). Thus, mammalian cells are the suitable alternative for the
2monoclonal antibody production. The protein expressed by the mammalian cells 
proving that the glycosylation has taken place where carbohydrates (glycan) has been 
added to the synthesized protein (Butler, 2005).
The mammalian cell expressed antibody is a better option compared to the 
bacteria. In the biopharmaceutical industry, the ability of the cell to produce in high 
titer is very important. Many researches have been done on the optimization of the 
bioprocessing in mammalian cell culture in order to achieve high antibody titer at 
lower cost. This study focuses on evaluating the multi-well based system which is an 
alternative to the flask cultures in the upstream processing. The multi-well plate is 
one of the tools that applies multi-well based system and will be evaluated in the 
study. The evaluation was determined by the growth rate of cell, cell metabolism and 
antibody expression of CHO cell cultured in 24 multi-well plate.
1.2 Problem Statement
In the biopharmaceutical industry, it is crucial for the company to be able to 
produce large amount of therapeutic protein in order to fulfill its high demand. Thus, 
many companies build large scale manufacturing plant that consists of large cell 
culture bioreactors as the response to the high demand.
However, large scale production is not cost-effective as the focus has shifted 
from controlling product quality and process consistency towards producing larger 
capacity of therapeutic protein (Li et al., 2010). Thus, higher cost is needed to 
provide more material in order to pursue higher titer. In the end of the day, the 
quality of product produced might be not up to par to the standardized quality of the 
therapeutic protein as the cell screening is hard to do in large scale. Therefore, cell 
line generation and selection followed by process and media optimization need to be 
done in small scale before going to the larger scale which requires more funding.
3Multi-well based system is one of the useful scale down of larger reactors 
(Girard et al., 2001). This system is making the job in generating and screening the 
cell line easier due to its small scale. Multi-well based system also able to produce 
high throughput in a miniature scale. Thus, it is cost-effective as it only needed small 
amount of materials. Thus, this study will evaluate the multi-well based system 
according to the growth rate of CHO cell and antibody expression.
1.3 Objective of Study
The aims of this study are:
1. To determine the growth rate of CHO cell in 24 multi-well plate.
2. To determine the glucose content of two types of CHO cell.
3. To verify the antibody expression of CHO DG44 cell.
1.4 Scope of Study
In this study, the multi-well based system was evaluated. Two types of CHO 
cells which are the wild type CHO cell and CHO DG44 was seeded into the 24-well 
microplate with different seeding density. The growth rate of the CHO cell and 
glucose content was analyzed. Besides that, the antibody expressed by CHO DG44 
was determined by analyzing its presence in the media proving that it is successfully 
expressed and secreted in the media. Lastly, multi-well based system was concluded 
whether it is suitable for the cell growth and works as ‘microreactor’.
41.5 Significance of Study
Through this research, one of the multi-well based systems which are multi­
well plate was evaluated. The outcome of this study would provide foundation for 
the future bioreactor and animal tissue culture research on the production of 
monoclonal antibody. Besides that, multi-well plate can be applied as an alternative 
to the flask culture. In addition, multi-well plate can be used as ‘microreactor’ and 
works as one of the high throughput technology that be able to produce high 
antibody titer in small scale. In this system, only small amount of raw material 
needed thus reducing the cost and time consumption needed. Thus, helps to improve 
the upstream processing for the monoclonal antibody production in 
biopharmaceutical industry besides promoting safer, low cost and time efficient 
system for high production of monoclonal antibody. Lastly, this study helps to fulfill 
market demand on therapeutic protein for wide population of patient.
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